MedTrace Logo

Non-invasive Monitoring: Impact on Patient Management and Outcomes

NCT06270953 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2025-09-29

No results posted yet for this study

Summary

Enhancing patient monitoring in SNFs and ALFs is crucial due to challenges in recognizing deteriorating health. Gaps in vital sign checks lead to missed indicators and adverse outcomes. Turtle Shell Technologies' Dozee Pro NX offers continuous non-invasive monitoring, alerting healthcare providers of vital sign changes. This clinical study aims to evaluate Dozee Pro Nx's impact on patient outcomes, practitioner efficiency, and healthcare costs in SNFs and ALFs, addressing gaps in care delivery.

Conditions

  • No Specific Medical Conditions or Disease States

Interventions

DEVICE

Dozee Pro NX

Dozee Pro NX to measure Heart Rate, Respiratory Rate, SPO2 and movements

Sponsors & Collaborators

  • Turtle Shell Technologies Pvt. Ltd.

    lead INDUSTRY

Principal Investigators

  • Lindsay Darthard, LNFA · Oak Village Healthcare

Eligibility

Min Age
18 Months
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-19
Primary Completion
2024-04-30
Completion
2024-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06270953 on ClinicalTrials.gov